

EMA/659414/2022

European Medicines Agency decision P/0275/2022

of 10 August 2022

on the granting of a product specific waiver for N-(6-(((2R,3S)-3,4-dihydroxybutan-2-yl)oxy)-2-((4-fluorobenzyl)thio)pyrimidin-4-yl)-3-methylazetidine-1-sulfonamide (RIST-4721), (EMA-003223-PIP01-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Only the English text is authentic.

European Medicines Agency decision

P/0275/2022

of 10 August 2022

on the granting of a product specific waiver for N-(6-(((2R,3S)-3,4-dihydroxybutan-2-yl)oxy)-2-((4-fluorobenzyl)thio)pyrimidin-4-yl)-3-methylazetidine-1-sulfonamide (RIST-4721), (EMEA-003223-PIP01-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the application submitted by Aristea Therapeutics, Inc. on 23 March 2022 under Article 13 of Regulation (EC) No 1901/2006,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 24 June 2022 in accordance with Article 13 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee has given an opinion on the granting of a product specific waiver.
- (2) It is therefore appropriate to adopt a decision granting a waiver.

Has adopted this decision:

Article 1

A waiver for N-(6-(((2R,3S)-3,4-dihydroxybutan-2-yl)oxy)-2-((4-fluorobenzyl)thio)pyrimidin-4-yl)-3-methylazetidine-1-sulfonamide (RIST-4721), tablet, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 2

This decision is addressed to Aristea Therapeutics, Inc., 12770 High Bluff Drive, Suite 380, 92130 - San Diego, USA.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

EMA/PDCO/191368/2022
Amsterdam, 24 June 2022

Opinion of the Paediatric Committee on the granting of a product-specific waiver

EMA-003223-PIP01-22

Scope of the application

Active substance(s):

N-(6-(((2R,3S)-3,4-dihydroxybutan-2-yl)oxy)-2-((4-fluorobenzyl)thio)pyrimidin-4-yl)-3-methylazetidine-1-sulfonamide (RIST-4721)

Condition(s):

Treatment of palmoplantar pustulosis

Pharmaceutical form(s):

Tablet

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Aristea Therapeutics, Inc.

Basis for opinion

Pursuant to Article 13 of Regulation (EC) No 1901/2006 as amended, Aristea Therapeutics, Inc. submitted to the European Medicines Agency on 21 March 2022 an application for a product-specific waiver on the grounds set out in Article 11 of said Regulation for the above mentioned medicinal product.

The procedure started on 25 April 2022.

Opinion

1. The Paediatric Committee, having assessed the waiver application in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to grant a product-specific waiver for all subsets of the paediatric population and the above mentioned condition in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The grounds for the granting of the waiver are set out in Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

Grounds for the granting of the waiver

1. Waiver

1.1. Condition:

Treatment of palmoplantar pustulosis

The waiver applies to:

- all subsets of the paediatric population from birth to less than 18 years of age;
- tablet, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies are not feasible.